Spyre Therapeutics (SYRE) Analyst & Key Data

Analyst Consensus

Buy13 analysts

Buy

Updated Sep 12, 2026

Total Analysts13

Buy

12

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$90.60

DCF Value-98.65%

$1.22

Potential downside vs current price

Current Stock Price

$90.60

DCF Value-98.65%

$1.22

Potential downside vs current price

Analyst Consensus

Buy13 analysts

Buy

Updated Sep 12, 2026

Total Analysts13

Buy

12

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score3.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$90.60

DCF Value-98.65%

$1.22

Potential downside vs current price

Current Stock Price

$90.60

DCF Value-98.65%

$1.22

Potential downside vs current price

Spyre Therapeutics, Inc.